Chronic bronchitis, an inflammation of bronchial lining, characterized by persistent productive cough, dyspnoea and chest tightness. This study aims to provide new insights and treatment option with homoeopathic medicine as mucolytic and become beneficial in reducing symptoms.

Evaluation the comparative efficacy of homoeopathic mucolytic in chronic bronchitis: a randomized trial of senega officinalis, silphium, ammoniacum gummi and balsamum peruvianum using cat criteria - NIL

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078095

Enrollment

Registered

2024-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J418- Mixed simple and mucopurulent chronic bronchitis

Interventions

Intervention1: SENEGA OFFICINALIS : according to randomized process, i will give the any one medicine from taken 4 medicine. potency and repetition will be decide according to hahnemmans guideline giv

Eligibility

Inclusion criteria

Inclusion criteria: â?¢ Individual with diagnostic symptoms of chronic bronchitis â?¢ Age group between 40-70 years â?¢ Patient of both sexes â?¢ Patient from all socio economical status â?¢ Patient who are willing for chest x ray investigation (before-after treatment)

Exclusion criteria

Exclusion criteria: â?¢ Patient with severe respiratory function impairment â?¢ Patient with any malignant disease â?¢ Patient with severe comorbidities â?¢ Patient with autoimmune disorders â?¢ Patient present with most similimum medicine indication other then taken medicine for this synopsis

Design outcomes

Primary

Measure	Time frame
To evaluate the highest mucolytic effect of any one medicine from all of four medicine taken in study - Senega Officinalis, Silphium, Ammoniacum Gummi and Balsam Peruvianum in cases of chronic bronchitis along with their comparative analysis.Timepoint: 12 months , per patient 2 months	—

Secondary

Measure	Time frame
to assess the impact of these remedies on patients quality of life and respiratory function.Timepoint: 12 months per patient 2 months	—

Countries

India

Contacts

Public ContactDr Dhara Patel

Parul institute of homoeopathy and research, Parul University, Post Limda, Waghodia, Vadodara

dipika.sindha87141@paruluniversity.ac.in9978919488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026